Literature DB >> 19935445

New patterns in the otopathogens causing acute otitis media six to eight years after introduction of pneumococcal conjugate vaccine.

Janet R Casey1, Diana G Adlowitz, Michael E Pichichero.   

Abstract

OBJECTIVE: To describe NP and AOM otopathogens during the time frame 2007 to 2009, 6 to 8 years after the introduction of 7-valent pneumococcal conjugate (PCV7) in the United States and to compare nasopharyngeal (NP) colonization and acute otitis media (AOM) microbiology in children 6 to 36 months of age having first and second AOM episodes with children who are otitis prone.
METHODS: Prospectively, the microbiology of NP colonization and AOM episodes was determined in 120 children with absent or infrequent AOM episodes. NP samples were collected at 7 routine visits between 6 and 30 months of age and at the time of AOM. For first and subsequent AOM episodes, middle ear fluid (MEF) was obtained by tympanocentesis. Eighty otitis prone children were comparatively studied. All 200 children received age-appropriate doses of PCV7.
RESULTS: We found PCV7 serotypes were virtually absent: (0.9% isolated from both NP and MEF) in both study groups. However, non-PCV7 serotypes replaced PCV serotypes such that the frequency of isolation of S. pneumoniae (Spn) was nearly equal to that of non-typeable Haemophilus influenzae (NTHi). M. catarrhalis (Mcat) was less common and Staphylococcus aureus infrequent in the NP and MEF from the 2 groups. The proportion of Spn, NTHi and Mcat causing AOM was similar in children with first and second AOM episodes compared to otitis prone children. However, oxacillin-resistant Spn isolated from the NP and MEF was 19% for the absent/infrequent and 58% for the otitis prone groups, P < 0.0001. Beta-lactamase producing NTHi occurred more frequently in the otitis prone group, P = 0.04.
CONCLUSIONS: Six to 8 years after widespread use of PCV7, Spn strains expressing vaccine-type serotypes have virtually disappeared from the NP and MEF of vaccinated children. NP colonization and AOM has changed to non-PCV7 strains of Spn. NTHi continues to be a major AOM pathogen. The otopathogens in first and second AOM and in otitis prone children are very similar although Spn and NTHi are more often antibiotic resistant in the otitis prone.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19935445      PMCID: PMC3959886          DOI: 10.1097/INF.0b013e3181c1bc48

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  39 in total

1.  Epidemiology of acute otitis media caused by Streptococcus pneumoniae before and after licensure of the 7-valent pneumococcal protein conjugate vaccine.

Authors:  M Catherine McEllistrem; Jennifer Adams; Edward O Mason; Ellen R Wald
Journal:  J Infect Dis       Date:  2003-11-10       Impact factor: 5.226

2.  Colonisation by Streptococcus pneumoniae and Staphylococcus aureus in healthy children.

Authors:  D Bogaert; A van Belkum; M Sluijter; A Luijendijk; R de Groot; H C Rümke; H A Verbrugh; P W M Hermans
Journal:  Lancet       Date:  2004-06-05       Impact factor: 79.321

3.  Genetic basis for the new pneumococcal serotype, 6C.

Authors:  In Ho Park; Saeyoung Park; Susan K Hollingshead; Moon H Nahm
Journal:  Infect Immun       Date:  2007-06-18       Impact factor: 3.441

4.  Bacteriology of acute otitis media in a cohort of Finnish children followed for the first two years of life.

Authors:  T Kilpi; E Herva; T Kaijalainen; R Syrjänen; A K Takala
Journal:  Pediatr Infect Dis J       Date:  2001-07       Impact factor: 2.129

5.  Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente.

Authors:  Steven Black; Henry Shinefield; Roger Baxter; Robert Austrian; Laura Bracken; John Hansen; Edwin Lewis; Bruce Fireman
Journal:  Pediatr Infect Dis J       Date:  2004-06       Impact factor: 2.129

6.  Effect of the 7-valent pneumococcal conjugate vaccine on nasopharyngeal colonization by Streptococcus pneumoniae in the first 2 years of life.

Authors:  Faryal Ghaffar; Theresa Barton; Juanita Lozano; Luz Stella Muniz; Patricia Hicks; Vanthaya Gan; Naveed Ahmad; George H McCracken
Journal:  Clin Infect Dis       Date:  2004-09-13       Impact factor: 9.079

7.  Community-wide vaccination with the heptavalent pneumococcal conjugate significantly alters the microbiology of acute otitis media.

Authors:  Stan L Block; James Hedrick; Christopher J Harrison; Ron Tyler; Alan Smith; Rebecca Findlay; Eileen Keegan
Journal:  Pediatr Infect Dis J       Date:  2004-09       Impact factor: 2.129

8.  Changes in frequency and pathogens causing acute otitis media in 1995-2003.

Authors:  Janet R Casey; Michael E Pichichero
Journal:  Pediatr Infect Dis J       Date:  2004-09       Impact factor: 2.129

9.  Epidemiologic studies of Streptococcus pneumoniae in infants: acquisition, carriage, and infection during the first 24 months of life.

Authors:  B M Gray; G M Converse; H C Dillon
Journal:  J Infect Dis       Date:  1980-12       Impact factor: 5.226

10.  Effect of a nonavalent conjugate vaccine on carriage of antibiotic-resistant Streptococcus pneumoniae in day-care centers.

Authors:  Ron Dagan; Noga Givon-Lavi; Orly Zamir; Drora Fraser
Journal:  Pediatr Infect Dis J       Date:  2003-06       Impact factor: 2.129

View more
  129 in total

1.  Serum intercellular adhesion molecule 1 variations in young children with acute otitis media.

Authors:  Keyi Liu; Janet Casey; Michael Pichichero
Journal:  Clin Vaccine Immunol       Date:  2010-10-06

2.  When co-colonizing the nasopharynx haemophilus influenzae predominates over Streptococcus pneumoniae except serotype 19A strains to cause acute otitis media.

Authors:  Qingfu Xu; Janet R Casey; Arthur Chang; Michael E Pichichero
Journal:  Pediatr Infect Dis J       Date:  2012-06       Impact factor: 2.129

3.  Transcriptome signature in young children with acute otitis media due to Streptococcus pneumoniae.

Authors:  Keyi Liu; Linlin Chen; Ravinder Kaur; Michael Pichichero
Journal:  Microbes Infect       Date:  2012-01-23       Impact factor: 2.700

4.  Comprehensive Proteomic and Metabolomic Signatures of Nontypeable Haemophilus influenzae-Induced Acute Otitis Media Reveal Bacterial Aerobic Respiration in an Immunosuppressed Environment.

Authors:  Alistair Harrison; Laura G Dubois; Lisa St John-Williams; M Arthur Moseley; Rachael L Hardison; Derek R Heimlich; Alexander Stoddard; Joseph E Kerschner; Sheryl S Justice; J Will Thompson; Kevin M Mason
Journal:  Mol Cell Proteomics       Date:  2015-12-28       Impact factor: 5.911

Review 5.  Cellular immune response in young children accounts for recurrent acute otitis media.

Authors:  Sharad K Sharma; Michael E Pichichero
Journal:  Curr Allergy Asthma Rep       Date:  2013-10       Impact factor: 4.806

6.  Simultaneous assay for four bacterial species including Alloiococcus otitidis using multiplex-PCR in children with culture negative acute otitis media.

Authors:  Ravinder Kaur; Diana G Adlowitz; Janet R Casey; Mingtao Zeng; Michael E Pichichero
Journal:  Pediatr Infect Dis J       Date:  2010-08       Impact factor: 2.129

Review 7.  The host immune dynamics of pneumococcal colonization: implications for novel vaccine development.

Authors:  M Nadeem Khan; Michael E Pichichero
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

8.  Comparison of amoxicillin/clavulanic acid high dose with cefdinir in the treatment of acute otitis media.

Authors:  Janet R Casey; Stan L Block; Jim Hedrick; Anthony Almudevar; Michael E Pichichero
Journal:  Drugs       Date:  2012-10-22       Impact factor: 9.546

9.  Haemophilus influenzae-protein D specific antibody correlate with protection against acute otitis media in young children.

Authors:  Anthony Almudevar; Michael E Pichichero
Journal:  Vaccine       Date:  2018-02-01       Impact factor: 3.641

10.  Payment analysis of two diagnosis and management approaches of acute otitis media.

Authors:  Janet R Casey; Michael E Pichichero
Journal:  Clin Pediatr (Phila)       Date:  2014-05-09       Impact factor: 1.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.